Wexford Capital’s United Therapeutics UTHR Stock Holding History

Wexford Capital’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,000	Closed	-$943K	–	203
2022 Q2	$943K	Sell	4,000 -1,601	-29%	-$325K	0.05%	85
2022 Q1	$1M	Sell	5,601 -2,399	-30%	-$457K	0.05%	72
2021 Q4	$1.73M	Buy	+8,000	New	+$1.57M	0.07%	90
2021 Q2	$1.79M	Hold	10,000	–	–	0.27%	80
2021 Q1	$1.67M	Buy	10,000 +2,500	+33%	+$417K	0.25%	92
2020 Q4	$1.14M	Buy	+7,500	New	+$984K	0.18%	104

Other funds holding UTHR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Wexford Capital's UTHR Position: Q3 2022 in Review

Wexford Capital sold out of United Therapeutics (UTHR) in Q3 2022, closing a stake of 4,000 shares — an estimated $943K sold.

Wexford Capital first reported a position in UTHR in Q4 2020 and held it in 6 quarters. The position peaked at $1.79M in Q2 2021. 459 funds tracked by Wall St. Rank hold UTHR as of Q3 2022.

Wexford Capital reported no remaining United Therapeutics position as of Q3 2022 after selling out during the quarter.
Wexford Capital sold 4,000 United Therapeutics shares in Q3 2022, an estimated $943K.
Wexford Capital first reported a position in United Therapeutics in Q4 2020 and held it in 6 quarters.
Wexford Capital's United Therapeutics position peaked at $1.79M in Q2 2021.
459 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2022.

Based on Wexford Capital's 13F filing for Q3 2022, filed 14 Nov 2022.